ERBB2 and neoplasm: It has been postulated that trastuzumab deruxtecan is able to provide a robust clinical response and benefit via the “bystander killing effect”, whereby trastuzumab deruxtecan is internalized by HER2-positive cancer cells and the cytotoxic payload is then transferred to adjacent tumor cells with subsequent apoptosis of cancer cells [23].